Having identified the phenomenon of PD-L1 induction in target cells following the interaction with PD-L1–CAR effector cells, we have decided to interrogate the strategy to increase the precision of PD-L1–CAR-based therapy and the susceptibility of the tumor to this CAR. The gene discussed is CD274; the disease is neoplasm.